Prospective Study for Vaginal Vault Prolapse After Hysterectomy: Comparison of Two Surgical Methods

Vaginal Vault Prolapse Clinical Trial

Official title:

Prospective Randomized Study for Vaginal Vault Prolapse After Hysterectomy: Comparison of a Vaginal and Laparoscopic Method With Validation of Translated Questionnaire for Symptoms and Quality of Life by Vaginal Prolapse.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02290288
• Other study ID #: VGFOUREG-28601
• Status: Completed
• Phase: N/A
• First received: November 4, 2014
• Last updated: May 18, 2015
• Start date: October 2005
• Est. completion date: May 2015

Study information

• Verified date: May 2015
• Source: Sahlgrenska University Hospital, Sweden
• Contact: n/a
• Is FDA regulated: No
• Health authority: Sweden: Regional Ethical Review Board Sweden
• Study type: Interventional

Clinical Trial Summary

The study is carried out at the Sahlgrenska University Hospital and the patient population consists of women referred with symptomatic and bothersome post-hysterectomy vaginal vault prolapse at least 1 cm above or beyond the hymeneal remnants. The interventions are either vaginal sacrospinousfixation or laparoscopic sacrocolpopexy following randomization to one of the types of surgery. The primary outcome is anatomical failure based on clinical assessment. Failure is defined clinically, according to the Pelvic Organ Prolapse Quantification system, as Ba, C or Bp at the hymen or below on maximum Valsalva maneuver one and two years after the surgery. Secondary outcomes are evaluation of continence, sexual function and prolapse symptoms based on validated questionnaires 1, 2, 5 and 10 years after the surgery.

Description:

The lifetime risk for pelvic floor surgery for prolapse is likely to be between 10% and 15%, and a large number of patients who previously underwent hysterectomy develop vaginal vault prolapse. There is some evidence that about 2% of all women after hysterectomy would require a surgery for vault prolapse. There are many different techniques used for correction of vault prolapse but the evidence for them is lacking and the use is guided mainly by tradition at the singe institution.

There is some evidence indicating that laparoscopic surgery can be superior to the vaginal approach. Symptoms of prolapse are significantly associated with avulsion injury in patients after hysterectomy.

Our aim is to compare, with a 1- and 2-years follow-up examination in patients with post-hysterectomy prolapse, the efficacy of two standard surgical procedures for vaginal vault prolapse: sacrospinous vaginal colpopexy (the Richter procedure) with native tissue vaginal repair (sacrospinous fixation, SSF) and laparoscopic colposacropexy with mesh.

This is a single-center, randomized controlled trial of two standard surgical procedures for vaginal vault prolapse routinely used at our institution.Both procedures are designed to treat vault prolapse, one with mesh implantation through laparoscopy and the other with vaginal repairs and apical fixation to the sacrospinous ligament, usually on the right.

All patients referred to our gynecological unit (Ob/Gyn Department of Sahlgrenska University Hospital in Gothenburg) because of symptomatic vault prolapse and fulfilling the inclusions criteria are asked to participate in the study. Eligible for inclusion are: post-hysterectomy patients with at least two-compartment prolapse (with affected apical/vault compartment, stage II or higher on the Pelvic Organ Prolapse Quantification system (POP-Q)), suffering from symptoms of prolapse, requesting pelvic floor reconstructive surgery, and diagnosed with a vault prolapse. Excluded are: patients with prolapse and uterus in place, those not requesting pelvic floor surgery, patients who do not understand Swedish or are not capable to fulfill follow up procedure.

Patients undergo identical pre- and postoperative assessment procedures, including POP-Q examination on maximum Valsalva maneuver, which are archived on Case Report Form, and validated questionnaires PFDI-20, PFIQ-7 and PISQ-12. The study was approved by the regional ethics committee and all subjects obtain written informed consent to participate. To minimize the bias we decided that all the follow up examinations are going to be performed by the same gynecologist who do not perform the surgery.

All patients can end participation in the study at any moment.

The randomization process is carried out by computer, using patient social security number, at the time of enrollment (usually 2-3 months before the surgery). Patients are informed about their allocation after the randomization. Both procedures are performed by an experienced surgeon, with the patient under general anesthesia for the laparoscopic procedure and regional anesthesia for the sacrospinous fixation.

Patients are followed up at 3 months,1 year and 2 years postoperatively. These postoperative clinical examinations are performed by a single examiner, who had not been involved in the surgical procedures. The vaginal descent was assessed at maximum Valsalva maneuver.

In case of recurrence of prolapse and distressing symptoms which a patient desired to be resolved, a reoperation of prolapse is planned according to the clinical praxis at our department.

The primary outcome measure was anatomical failure based on clinical assessment. Failure was defined clinically as Ba, C or Bp at the hymen or below, on maximum Valsalva maneuver.

As secondary outcome measures we used a continence status, sexual function and prolapse symptoms based on validated questionnaires: Pelvic Floor Impact Questionnaire (PFIQ - 7), Pelvic Floor Distress Inventory Questionnaire - Short Form 20 (PFDI-20), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) and quality of life based on Short Form (36) Health Survey.

The power calculation was based on the primary outcome measure and available data which led us to expect a failure rate of 25% in the sacrospinous fixation group and 10% failure in laparoscopy group. To detect an expected difference of 15% between the groups, with 80% power of the test 70 patients are required in each group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 138
• Est. completion date: May 2015
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• post-hysterectomy patients with at least two-compartment prolapse (with affected apical/vault compartment,

• stage II or higher on the Pelvic Organ Prolapse Quantification system (POP-Q)),

• suffering from symptoms of prolapse,

• requesting pelvic floor reconstructive surgery, and

• diagnosed with a vault prolapse.

Exclusion Criteria:

• patients with prolapse and uterus in place,

• those not requesting pelvic floor surgery,

• patients who do not understand Swedish or are not capable to fulfill follow up procedure

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pelvic Organ Prolapse
• Prolapse
• Vaginal Vault Prolapse

Intervention

Procedure:
• vaginal surgery

• laparoscopic surgery

Locations

Country	Name	City	State
Sweden	Dept of Obst Gyn, Sahlgrenska University Hospital	Gothenburg	VGR

Sponsors (1)

Lead Sponsor	Collaborator
Sahlgrenska University Hospital, Sweden

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	anatomical failure (Failure was defined clinically as Ba, C or Bp at the hymen or below, on maximum Valsalva maneuver.)	The primary outcome measure was anatomical failure based on clinical assessment. Failure was defined clinically as Ba, C or Bp at the hymen or below, on maximum Valsalva maneuver.	1 year	No
Secondary	continence status	continence status based on validated questionnaires: Pelvic Floor Impact Questionnaire (PFIQ - 7), Pelvic Floor Distress Inventory Questionnaire - Short Form 20 (PFDI-20), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12)	1 and 5 years	No
Secondary	sexual function	sexual function based on validated questionnaires: Pelvic Floor Impact Questionnaire (PFIQ - 7), Pelvic Floor Distress Inventory Questionnaire - Short Form 20 (PFDI-20), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12)	1 and 5 years	No
Secondary	prolapse symptoms	symptoms based on validated questionnaires: Pelvic Floor Impact Questionnaire (PFIQ - 7), Pelvic Floor Distress Inventory Questionnaire - Short Form 20 (PFDI-20), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12	1 and 5 years	No
Secondary	quality of life	quality of life based on validated questionnaires: Pelvic Floor Impact Questionnaire (PFIQ - 7), Pelvic Floor Distress Inventory Questionnaire - Short Form 20 (PFDI-20), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) and quality of life based on Short Form (36) Health Survey.	1 and 5 years	No